Cboe Global Markets, Inc. (Cboe: CBOE) — A Toll Booth on Fear, Pricing Peak Volatility as Permanent

Date: June 2026 Price reference: ~$281.91 (June 5, 2026); ~104.7M diluted shares; market cap ~$29.5B; net cash ~$0.77B Sector: Financial Exchanges & Data (Capital Markets) Fiscal year: December 31 · HQ Chicago, IL

⚡ The Author’s Take

This opening block is my own subjective opinion and general information only — it is not investment advice. The analysis that follows (Sections 1–15) is deliberately position-free and carries no price target; this opener is the one place I take a directional view.

Verdict: HOLD a great business at a fair-to-full price — accumulate on weakness, do not chase. Conviction: Medium. Fair-value/accumulation zone ≈ low-$200s to ~$240 (≈ 20–22× a volatility-normalized ~$10.50–$11.00 of mid-cycle EPS); above ~$300 the stock is pricing peak-cycle volumes as permanent. Today’s ~$282 (down ~24% from the $371 52-week high) is roughly fair — neither a fat pitch nor a short.

Tag: “A toll booth on fear — own the booth, don’t overpay for a panic.”

Cboe owns one of the best assets in public markets: a contract-protected monopoly on the SPX and VIX complex, where revenue-per-contract runs ~14× the commoditized multi-listed business, adjusted operating margins sit near 66%, ROE is ~23%, and the balance sheet is net cash. That franchise is outside the normal competitive capital cycle — regulation and an exclusive S&P license suspend the supply response that is, in plain sight, eroding Cboe’s other (multi-listed options, cash-equities) businesses. This is a genuine moat, and new CEO Craig Donohue is making the right disciplined moves (exiting crypto, Canada/Australia, Japan, CEDX; ~20% headcount cut; buyback paused at the highs). What the market is mispricing is how much of FY2025–Q1’26’s record results is cyclical. 2025 was the sixth straight record year for US options on an unusually volatile tape (VIX closed 52.33 in April 2025); management’s own 2026 guide of mid-single-digit organic growth, after +17% net-revenue growth in 2025, is a quiet admission that the run-rate isn’t the trend. At ~24× trailing adjusted EPS for a business that is still ~74% transaction/volume-driven, you are underwriting a large slice of peak volume as durable.

Two things keep this a HOLD rather than a BUY: (1) volatility mean-reversion — a sustained low-vol regime compresses VIX and 0DTE volumes and de-rates the multiple; and (2) the 2032/2033 S&P license cliff — the crown jewel is ultimately a renewable lease on someone else’s index, and a multiple driven by terminal value should not ignore a finite contract that is “the first risk factor” in the 10-K. What flips me bullish: the stock into the low-$200s/high-$100s, or hard evidence that 0DTE/index volumes hold through a genuine low-vol stretch (two+ quarters of sub-16 VIX without SPX ADV rolling over). What flips me bearish: any sign the S&P relationship is renegotiating on worse terms (or S&P internalizing index derivatives), or a return to large, non-core “growth” M&A that revives the ErisX-style empire-building that already cost shareholders ~$461M.

1. Executive Summary

Cboe Global Markets operates the largest US options exchange complex and the world’s pre-eminent volatility franchise. Its economic engine is narrow and deep: the proprietary, single-listed S&P 500 (SPX) options and VIX volatility complex, products no other exchange may list, supported by an exclusive license from S&P Dow Jones Indices and the proprietary VIX methodology. Around this core sit four other segments — North American Equities, Europe & Asia Pacific, Futures, and Global FX — plus Cboe Data Vantage, a recurring market-data and access/connectivity business (~26% of net revenue) that provides ballast against transaction cyclicality.

The business is, in effect, two companies wearing one ticker. The proprietary tier (SPX/VIX; ~63% Options + ~5% Futures = ~68% of net revenue) is a regulated, contract-protected near-monopoly with ~14× the revenue-per-contract of the commodity tier and no on-exchange competitor. The contestable tier (multi-listed options, US/European cash equities) is a low-switching-cost, rebate-driven business steadily losing share into a supply boom of new exchanges (MIAX, MEMX). The first is a wide moat; the second is a melting ice cube. That bifurcation is the entire investment debate.

FY2025 was a record year — net revenue $2,429.1M (+17%), GAAP diluted EPS $10.42, adjusted diluted EPS $10.67, net income $1,100.0M, GAAP operating margin 60.4%, ROE ~23%. Q1 2026 set fresh records (net revenue $728.9M, +29%; adjusted EPS $3.70, +48%). But these results coincided with an exceptionally volatile macro tape, and management guides 2026 organic net-revenue growth to mid-single digits — a tacit concession that 2025’s pace is not the steady state. Two quality-of-earnings nuances matter: FY2025 GAAP EPS was flattered by ~$96.8M of one-time investment gains (adjusted EPS strips them, the rare case where adjusted exceeds GAAP), and FY2025 operating cash flow was inflated ~$528.5M by Cboe Clear margin/clearing-fund timing (core OCF ~$1.2B, not the reported $1.75B).

Capital allocation is bimodal: the Bats acquisition (2017) was foundational and value-creating; the ErisX/Cboe Digital crypto venture (2022) was a clear value-destroyer ($460.9M goodwill impairment within months of closing, spot business wound down 2024). New CEO Craig Donohue (ex-CME, ex-OCC; in seat since May 2025) is executing a credible course-correction toward core-derivatives focus. The balance sheet is conservative (net cash; ~0.8–0.9× leverage), the dividend has compounded for ~15 years, and buybacks were deliberately paused at the highs — a constructive price-discipline signal.

The defining risks are (1) volatility mean-reversion, which would deflate the volume-driven majority of revenue, and (2) the S&P license cliff (exclusive SPX rights to Dec 31, 2032; full license to Dec 31, 2033), the single largest concentration risk and the 10-K’s first-listed risk factor. At ~24× trailing adjusted EPS, the market is capitalizing a meaningful fraction of peak-cycle volumes as durable. This analysis takes no position and sets no price target; it frames the valuation as embedded expectations and scenarios.

2. Business Overview

2.1 What Cboe does

Cboe Global Markets — founded 1973 as the Chicago Board Options Exchange, the first US listed-options market, renamed Cboe Global Markets in 2017 — operates regulated exchanges and trading venues across options, cash equities, futures, and FX in North America, Europe, and Asia-Pacific. It earns money two ways:

1. Transaction and clearing fees — charged per options contract, equity share, futures contract, or FX trade matched on its venues (and cleared, where Cboe operates clearing). This is the cyclical, volume- and volatility-sensitive majority (~74% of net revenue).
2. Cboe Data Vantage (formerly Data & Access Solutions) — recurring subscription revenue for market data, plus access and capacity fees (connectivity, ports, terminals, co-location/floor space), Cboe Global Indices, and risk/market analytics. ~26% of net revenue and the structural-growth, lower-cyclicality engine. Data Vantage is not a separate reporting segment; its revenue is distributed across the five segments.

2.2 The gross-vs-net revenue distinction (critical)

Cboe reports total (gross) revenues and, separately, “revenues less cost of revenues” (net revenue) — and the gap is enormous and noisy. Gross revenue includes large pass-throughs: liquidity payments (maker-taker rebates routed straight back to liquidity providers), routing & clearing, Section 31 fees (an SEC pass-through), and royalty fees (paid to S&P DJI and other index licensors). FY2025 gross revenue was $4,714.2M but net revenue was $2,429.1M; the ~$2.3B difference is mostly rebates and pass-throughs that never touch Cboe’s economics. Net revenue is the only meaningful top line, and every figure here uses it unless stated. (Section 31 fees in particular gross-up revenue and cost equally — they distort gross revenue and conventional price-to-sales ratios but have ~zero margin effect; the SEC Section 31 rate fell to $0 from May 2025.)

2.3 Net revenue bridge and segments

Options + Futures = $1,657.3M = 68.2% of net revenue, the majority of it SPX and VIX. Cboe Data Vantage = $635.5M (26.2%) of net revenue (FY24 $576.6M; FY23 $539.2M), the recurring layer. The Digital segment was folded into Futures effective Q1 2025.

2.4 Revenue per contract (RPC) — where the money is

The single most important operating statistic Cboe discloses is RPC — net transaction fees ÷ contracts traded. FY2025 full-year:

Index options earn ~14× the multi-listed rate because they are single-listed and face no on-exchange price competition. Index options ADV was a record 4.9M contracts in FY2025 (+21%); total market ADV 60.8M (+25%). Cboe-reported full-year SPX (~970.6M) and VIX (~215.6M) contract totals come from Cboe’s monthly volume reports rather than the 10-K and are best treated as company-reported operating data.

2.5 Recurring vs. non-recurring

~74% of net revenue is transaction/clearing (recurs only insofar as volumes do); ~26% is genuinely recurring (Data Vantage market data + access/capacity). The recurring share is slowly rising as Data Vantage outgrows some transaction lines, but the swing factor for any given year remains index-options volume.

Verdict: A high-quality, capital-light, two-tier exchange business whose economics are dominated by a single proprietary product family. The model is well understood; the durability question is entirely about the mix between the monopoly tier and the commodity tier — and about how cyclical the monopoly tier’s recent volumes prove to be.

3. Industry Dynamics

3.1 Structure: a vertically integrated oligopoly

The global exchange industry is an oligopoly of vertically integrated operators, each with a defensible center of gravity:

• CME Group — interest-rate, equity-index, FX, energy, metals, and agricultural futures, with owned clearing.
• Intercontinental Exchange (ICE) — energy/commodity futures, NYSE cash equities/listings, fixed-income and mortgage-technology data.
• Nasdaq — listings franchise plus a growing market-technology / anti-financial-crime / index software business.
• LSEG — data and analytics (Refinitiv) and clearing (LCH).
• Deutsche Börse — Eurex European derivatives and data.
• Cboe — US listed options and the volatility complex (SPX/VIX), plus cash equities (US, Europe), FX, and Data Vantage.

3.2 Barriers to entry — high at the operator level, asymmetric at the product level

Operating a national securities exchange requires SEC registration and ongoing self-regulatory-organization (SRO) obligations; operating a futures exchange/clearer requires CFTC oversight. Those are real barriers to becoming an operator. But they do not protect any individual multi-listed product, for one structural reason: the Options Clearing Corporation (OCC) is the sole clearer for all US listed options. Because every venue clears through the same utility, a multi-listed options contract is fungible across exchanges — an order can be routed to whichever venue offers the best price/rebate, with essentially zero switching cost. New entrants therefore win share simply by offering richer rebates or differentiated market models.

3.3 The capital cycle in action — proliferation of options exchanges

This fungibility is why options exchanges proliferate. Cboe’s four options markets (C1, C2, BZX, EDGX) now compete with roughly 14 other US options exchanges (≈18 total), with two more expected in H1 2026 (~20), “in large part due to existing exchange holding companies opening new exchanges on existing technology” (10-K). MIAX runs four (Options, Pearl, Emerald, Sapphire); MEMX received SEC approval (October 2025) for a second options exchange (MX2), launching Q2 2026. On the equities side, Cboe’s four equities venues compete with 13 other exchanges and 25+ ATSs.

This is a textbook capital-cycle signal: record industry profitability (record volumes, the 0DTE boom) is pulling capital and supply into the commodity tier exactly as theory predicts, and the predictable consequence is continued fee/rebate compression and share erosion in multi-listed options and cash equities. The proprietary tier, by contrast, sits outside the capital cycle — regulation plus the exclusive license suspend the supply response, so capital literally cannot enter to compete SPX/VIX rents away.

3.4 Structural tailwinds and threats, quantified

• 0DTE (zero-days-to-expiry) options — the dominant structural driver. SPX 0DTE was ~59% of full-year-2025 SPX volume (record ADV ~2.3M contracts; ~50% of all index options trading on Cboe’s markets in Q1 2026). 0DTE has gone from novelty to the core volume pool of the crown jewel. Its durability through a normal-volatility regime is the single biggest open question in the thesis.
• Retail participation — retail was roughly half of total US options volume in 2025. Cboe argues the flow is durable (over 95% of 0DTE trades are limited-risk long options/spreads; retail pulls back during vol spikes but returns when vol abates) — supportive but not conclusive across a full low-vol cycle.
• Regulatory — two important developments. (a) The SEC withdrew the proposed Order Competition Rule and Regulation Best Execution (June 2025), removing a multi-listed/equities overhang. (b) The SEC adopted tick-size/access-fee reform (Rules 610/612, September 2024; upheld by the D.C. Circuit October 2025; compliance ~November 2025), which compresses cash-equities net capture — a headwind to the lower-margin North American Equities segment, not the index franchise. This regulatory asymmetry (pressure on the commodity tier, none on the proprietary tier) reinforces the bifurcation.

Verdict — structurally GOOD but sharply BIFURCATED. The proprietary tier is a regulated, contract-protected, monopoly-grade franchise. The multi-listed/cash-equities tier is a commoditizing rebate scrum with no durable barriers. A single “industry verdict” is misleading; the only verdict that matters is the mix.

4. Competitive Position

4.1 The moat, named precisely

Cboe’s moat is an intangible-asset advantage — the exclusive S&P DJI license plus the proprietary VIX methodology and the “VIX / fear gauge” brand — fused with economies-of-scale / liquidity captivity in the single-listed products. This is the strongest, most durable advantage class: a demand-side captivity (no fungible substitute venue) reinforced by a supply-side intangible (exclusive IP/license) and scale (liquidity begets liquidity in a single order book).

The crux, verified from the FY2025 10-K:

• “Our license with S&P extends through December 31, 2033, with exclusive rights to trade S&P 500 Index options through December 31, 2032.” Exclusive US rights also cover S&P 100, S&P 500 ESG, and S&P Select Sector indices.
• The VIX is calculated from real-time SPX option quotes. This creates a closed, self-reinforcing ecosystem: SPX liquidity feeds the VIX calculation; VIX futures/options drive SPX hedging flow back into the SPX book. Cboe holds exclusive proprietary rights to the VIX methodology itself — arguably a more durable lever than the S&P license because it is owned IP rather than a lease (though IP can be litigated and worked around).
• “The loss of our right to exclusively list and trade certain index options and futures products” is the FIRST risk factor in the 10-K — management’s own ranking of the company’s largest vulnerability.

4.2 Does the moat show up in financial outcomes?

Yes, unambiguously, and that is the test of a real moat:

• Pricing power: index RPC ~$0.924 vs multi-listed ~$0.066 (~14×). Where there is no competitor, Cboe sets price; where products are fungible, price is competed to the rebate.
• Margins: FY2025 GAAP operating margin 60.4% of net revenue; adjusted operating margin ~66%. These are among the highest in finance and are a direct read-out of the proprietary franchise.
• Returns: ROE ~23% on ~$5.1B of equity. Return on tangible capital is far higher — the matching-engine business needs almost no tangible capital, and ~$4.45B of goodwill+intangibles (mostly Bats) means tangible common equity is only ~$0.69B; on that base the franchise earns extraordinary returns. (Tangible-equity ratios are not meaningful here precisely because the moat is intangible — use ROE/ROIC.)

If the SPX/VIX exclusivity disappeared, index RPC would collapse toward the multi-listed rate and margins would compress sharply — the textbook definition of a moat tied to a financial outcome that deteriorates without it.

4.3 Where the moat does NOT protect — share erosion

In the contestable tier, Cboe is losing share, on schedule with the capital cycle:

Where is it going? MIAX reached a record ~18.2% options share in Q4 2025 (+14.5% YoY); MEMX is ~4% and adding a second exchange (MX2) in Q2 2026. A −1.4pp one-year drop in US equities share is a meaningful signal that there are no barriers in the commodity tier — the market-share-stability test fails there even as it passes perfectly (0% on-exchange competition) in the proprietary tier.

4.4 Pressure-test: durable moat, or a contractual lease that expires?

Honestly, both. On-exchange competition in SPX/VIX is impossible today — a true monopoly. But the SPX leg rests on a renewable contract with a 2032/2033 cliff, against a counterparty (S&P Global) that has its own index-derivatives ambitions and undisclosed renewal economics. The more insidious erosion risk is economic substitution outside the exclusivity perimeter — the 10-K itself names SPY options, mini/cash-settled index products, and event/prediction markets that can replicate SPX-like exposure without needing the S&P license. The VIX methodology (owned IP) is more defensible than the SPX license (a lease), which is one reason the volatility complex may outlast any single licensing arrangement.

Verdict — a DURABLE, contract-protected advantage in the proprietary franchise (no peer); a CROWDED, eroding commodity in multi-listed/equities. The differentiation is genuine and shows up directly in pricing and margins, but it is concentrated and contractually finite, and the durability debate reduces to two variables: the license cliff and the permanence of 0DTE.

5. Growth History and Forward Opportunities

5.1 The decade in numbers

Net revenue: 2019 ~$1.11B → 2020 $1.27B → 2021 $1.476B → 2022 $1.742B → 2023 $1.918B → 2024 $2.072B → 2025 $2.429B. Adjusted diluted EPS: 2019 $4.73 → 2021 $6.05 → 2023 $7.80 → 2024 $8.61 → 2025 $10.67. That is a high-single/low-double-digit net-revenue compounding rate with faster EPS growth (operating leverage + a steady ~2% annual reduction in share count).

5.2 Organic vs. acquired

The 2017–2021 step-change in the base was overwhelmingly acquired — Bats (2017), then Hanweck, Trade Alert, MATCHNow, Chi-X Asia Pacific, EuroCCP, NEO/Cboe Canada, and ErisX. Post-2022, growth has been predominantly organic, driven by the SPX/VIX/0DTE complex and Data Vantage. Management began guiding to “organic” net-revenue targets precisely to separate the bought-in platform from the home-grown engine. The candid read: Cboe bought a diversified global platform, then the organic core (proprietary index + recurring data) became the actual growth driver — and management is now unwinding much of the bought-in periphery (Canada, Australia, Japan, CEDX).

5.3 Forward vectors, stress-tested

• SPX / VIX / 0DTE — the strongest and most durable vector, but increasingly mature: 0DTE is already ~59% of SPX. New daily-expiration products (DJX dailies, Russell 2000, “Magnificent 10” / MGTN) extend the franchise incrementally, not transformationally.
• Data Vantage — the cleanest secular story: recurring, high-margin, internationally weighted (a rising share of new data sales is outside the US; 45% of new sales international in Q1’26 vs 35% a year earlier). 2026 guidance ~mid-to-high single-digit organic growth.
• 24×5 / overnight and international access — small but growing; SEC approved extended options hours (May 2026); APAC is a vector for giving global investors access to SPX.
• New asset classes / optionality — crypto derivatives (retained on CFE after the spot wind-down), prediction/event markets (a patent-pending Mini-SPX framework planned Q2 2026, OCC-cleared), Bitcoin/Ether continuous futures (Dec 2025), tokenization. Real optionality, but management explicitly assumes only modest 2026 revenue from these — and the ErisX history argues for skepticism on new bets.

5.4 Are the durable franchises also the growing ones?

Largely yes — SPX/VIX/0DTE and Data Vantage are both the most defensible and the fastest-growing parts of the business. That alignment is the bull case’s strongest structural pillar. The caveat is cyclicality: a large fraction of 2025’s index-volume growth rode an unusually volatile tape (VIX closed 52.33 on April 8, 2025; nine of the ten highest SPX volume days on record occurred in Q4’25–Q1’26). Management’s mid-single-digit 2026 organic guide — after +17% in 2025 — confirms that 2025’s pace is not the run-rate.

Verdict — high-quality growth, but cyclically amplified. The structural drivers (0DTE adoption, recurring data) are genuine and aligned with the moat; the recent rate of growth is inflated by a volatility peak and should be normalized before extrapolation.

6. Financial Quality

6.1 Profitability and margins

*FY22 operating income was depressed by the $460.9M ErisX/Digital goodwill impairment. Q1’26: operating income $505.6M, net income $385.7M, GAAP EPS $3.66, adjusted EPS $3.70 (+48% YoY).

Margins are excellent and improving as the realignment strips lower-margin units. The trajectory (op margin 53.0% → 60.4% from FY24 to FY25) reflects both volume leverage and mix shift toward the proprietary tier and Data Vantage.

6.2 Quality-of-earnings flags (important)

Two nuances materially affect how one should read FY2025:

1. GAAP EPS was flattered, not penalized, by adjustments. FY2025 GAAP diluted EPS of $10.42 included ~$96.8M of one-time investment gains (e.g., PYTH/7Ridge stakes). Adjusted EPS ($10.67) strips these gains and adds back amortization of acquired intangibles (~$69.9M) and realignment/impairment items (~$46.7M impairment + ~$7.0M realignment). This is the rare case where adjusted EPS exceeds GAAP because of one-time gains — a reader who anchors to GAAP EPS growth (+45% YoY) overstates the underlying trend.
2. Operating cash flow was inflated by clearing flows. Reported FY2025 OCF of $1,752.6M was boosted ~$528.5M by a Cboe Clear margin/clearing-fund inflow (a balance-sheet flow, not earnings) and swung by Section 31 payable timing (−$181.8M). Core/normalized OCF was ~$1.2B. Quarterly OCF (Q1’26 $1,960.0M) is even more distorted and must never be annualized naively.

Otherwise the accounting is clean and conservative: the GAAP-to-adjusted gap is modest, SBC is low (see below), and the main reconciling items are well-disclosed (intangible amortization, periodic impairments, one-time gains).

6.3 Cash flow, capex, SBC

The business is very capital-light — capex ~3% of net revenue ($73–83M guided for 2026), D&A falling as acquired intangibles roll off (~$63M of intangible amortization guided 2026). SBC is just $50.4M (~2.1% of net revenue) — low for the sector, with minimal dilution. Normalized FCF (~$1.1B) is the figure to use for yield; the reported $1.68B is not a clean run-rate.

6.4 Balance sheet

Debt is $1,450M face across three notes — $650M @3.650% (Jan 2027), $500M @1.625% (Dec 2030), $300M @3.000% (Mar 2032) — with an undrawn revolver. With $2.22B cash and ~$1.1B annual net income, net leverage is ~0.8–0.9× and the company is in a net-cash position — investment-grade with ample flexibility. (Note: a portion of “cash” relates to clearing operations; Cboe Clear funds of ~$1.6B sit on-balance-sheet and offset.)

6.5 Unit economics and scale

The clearest read on whether economics improve with scale is the RPC structure and incremental margins. Each additional SPX/VIX contract costs almost nothing to match and clear, so incremental margin on proprietary volume approaches 100% — which is exactly why operating margin expands with volume. The honest caveat: a meaningful slice of FY2025’s record profitability is cyclical (volatility-driven volume), so reported ROE/ROIC overstate the mid-cycle return.

Verdict — economics clearly improve with scale, and the proprietary franchise earns extraordinary returns on tangible capital. The two caveats are that (a) headline FY2025 cash flow and GAAP EPS are distorted (one up by clearing flows, the other up by one-time gains), and (b) the peak-cycle margin/return level is not the normalized level.

7. Capital Allocation

7.1 The framework

Management’s stated philosophy: invest in organic growth, grow the dividend, repurchase opportunistically, pursue bolt-on M&A, and keep leverage low. The record splits cleanly into excellent core/distribution capital deployment and poor “growth optionality” bets.

7.2 M&A scorecard — bimodal

• Bats Global Markets (closed Feb 28, 2017, ~$3.2B) — the foundational, value-creating deal. It gave Cboe a modern technology stack (onto which it migrated its options markets), US/European cash equities, ETF listings, BZX self-listing, and FX (Hotspot). Strategically coherent and broadly accretive.
• 2020–21 bolt-ons (Hanweck, Trade Alert, MATCHNow, EuroCCP, Chi-X APAC, NEO/Cboe Canada) — mixed. They built Data Vantage and the international footprint but added integration complexity; several are now being divested or wound down, evidence they under-earned.
• ErisX / Cboe Digital (closed May 2, 2022) — the clear value-destroyer. A $460.9M goodwill impairment was taken in 2022, within months of closing; the spot crypto business was wound down in 2024; futures migrated to CFE in June 2025 and Digital was folded into Futures. A classic case of chasing a hot trend outside core competence.
• 2025–26 realignment / divestitures — agreed (April 22, 2026) to sell Cboe Canada + Cboe Australia to TMX Group for ~US$300M (~C$409M); those units generated ~$87M revenue and ~$25M adjusted EBITDA in 2025 (≈3.4× revenue / ≈12× EBITDA exit). Plus wind-downs of Japan equities, CEDX (Cboe Europe Derivatives), US/European corporate listings, and smaller risk/analytics units. FY2025 carried ~$46.7M of related impairments (Japan $23.4M, Canada $17.7M, CEDX/Clear Europe $5.6M).

The pattern: Cboe created value buying infrastructure adjacent to its core (Bats) and destroyed value chasing trends outside it (crypto). The Donohue-led realignment is a credible correction toward disciplined focus.

7.3 Buybacks and dividends

The dividend has compounded for ~15 consecutive years; the quarterly rate was raised ~14% in August 2025 (to $0.72; $2.88 annualized) at a conservative ~26% payout. Buybacks are deliberately opportunistic and lumpy: all of FY2025’s $65.3M was bought early in the year at an average ~$214, and zero was repurchased in Q4’25 as the stock hit 52-week highs near $371. Cash was allowed to build instead (US cash +$1.3B YoY). Remaining authorization was $614.5M at year-end 2025, $569.4M at March 31, 2026. Letting cash build rather than buying at the peak is a constructive price-discipline signal — management implicitly judged the stock fully valued. Whether and at what price buybacks resume is a useful internal valuation tell to watch.

7.4 Incentives and alignment

CEO Craig Donohue’s realized 2025 total compensation was $18,347,037 — inflated by a one-time $6.0M sign-on equity grant (3-year cliff vesting); the ongoing structure is base $1.30M, target annual incentive 150% of salary (Adjusted EBITDA + net revenue + individual metrics), and LTI split 50% time-based RSUs / 50% PSUs (PSUs = 25% relative-TSR + 25% EPS, 3-year cliff). Governance hygiene is strong: 6× salary CEO ownership guideline, full anti-hedging and anti-pledging policies, and mandatory + supplemental clawbacks. COO Chris Isaacson retired March 2026 (consulting through year-end 2026 for ~$541,666).

The honest read: pay is performance-linked and well-governed, but personal skin-in-the-game is thin. All directors/NEOs/officers together own <1% (~0.25%); Donohue personally held just 2,604 shares. Institutional ownership is very high (Vanguard ~12.1%, BlackRock ~9.0%, AllianceBernstein ~6.5%). This is typical of a demutualized exchange — alignment is via equity compensation, not via meaningful insider ownership.

Verdict — competent-to-good capital allocation in the core franchise and distribution, undermined historically by the ErisX misadventure. The current regime is credibly disciplined (price-sensitive buybacks, divesting non-core, low leverage, rising dividend). The watch-item is any return to large, non-core “growth” M&A.

8. Major Changes and Headwinds — Last Two Years

• Leadership. Ed Tilly, CEO for over a decade, resigned September 19, 2023 after a board investigation found he failed to disclose personal relationships with colleagues — a governance black eye. Director and ex-TD Ameritrade CEO Fredric Tomczyk stabilized the company and exited crypto; Craig Donohue (ex-CME CEO 2004–2012; ex-OCC Executive Chairman/CEO) became CEO May 7, 2025, with heavy concurrent C-suite turnover.
• Strategic realignment (announced October 2025). A deliberate pivot from global expansion to core-derivatives focus: divest Canada/Australia (to TMX), wind down Japan equities, CEDX, and US/European listings; ~20% workforce reduction (headcount fell to 1,661 at YE25); and a combined $100–120M annualized cost-savings program (~$20–25M realized in 2026; FY2026 adjusted-opex guide lowered to $838–853M).
• Branding/segment changes. Data & Access Solutions → Cboe Data Vantage; Digital folded into Futures (Q1 2025); five reportable segments.
• Product launches. DJX daily options (2025/2026), nearly-24-hour Russell 2000 index options, “Magnificent 10” (MGTN), Bitcoin/Ether continuous futures (Dec 2025), a prediction-market/event-contract framework (Mini-SPX planned Q2 2026), and SEC-approved extended/24×5 options hours (May 2026).
• Competitive pressure. Multi-listed options and US-equities share eroded (total options 30.3% vs 30.8%; US equities 10.0% vs 11.4%), with MIAX and MEMX gaining.
• Regulation. SEC tick-size/access-fee reform (effective ~November 2025) compresses cash-equities net capture; the SEC’s withdrawal of the Order Competition Rule and Reg Best Execution (June 2025) removed an overhang on the same lower-margin tier.

Verdict — net thesis-neutral-to-modestly-positive, with execution risk. The core SPX/VIX franchise is untouched and strengthening; the changes (crypto exit, periphery divestitures, cost cuts, disciplined CEO) tighten focus. The headwinds (share erosion, cash-equities regulation) hit the commodity tier, which is the part that matters least.

9. Risk Analysis (Risk Matrix)

The risk profile is asymmetric: most likely risks (commodity-tier share loss) carry low impact, while the highest-impact risks (vol mean-reversion, license loss) are the ones that actually drive the thesis. Total-loss risk is negligible given the balance sheet.

10. Valuation Discussion (Embedded Expectations)

No price target and no recommendation. This section frames what the price implies.

10.1 Current multiples (≈$281.91, June 5, 2026)

• Market cap ~$29.5B (~104.7M shares); EV ~$28.7B (net cash ~$0.77B).
• Trailing P/E ~24× on TTM adjusted EPS (~$11.9, through Q1’26); ~27× on FY2025 GAAP EPS ($10.42).
• Forward P/E ~20–22× (consensus reflects continued 2026 momentum).
• EV/EBITDA ~16–18×.
• Normalized FCF yield ~3.8–4% (on ~$1.1B normalized FCF); dividend yield ~1.0%.
• Own-history valuation (vs trailing ~10y): P/E ~44th percentile (mid), P/B ~87th (rich), P/S ~81st (rich). The P/E percentile is only mid because earnings grew so fast; on book and sales the stock is rich versus its own past.

10.2 Peer comparison (June 5, 2026)

CBOE sits mid-pack: cheaper than CME/NDAQ on EV/EBITDA, a premium to ICE. (Price-to-sales is not comparable across this group because of differing gross-revenue pass-throughs; on net revenue CBOE trades ~12× sales.) Versus its own ~27–28× five-year median P/E, the current ~24× trailing is modestly below its recent norm — reflecting the ~24% drawdown from the $371 high and concern that 2025’s volume records are unrepeatable.

10.3 Embedded-expectations / sum-of-the-parts logic

The right way to value Cboe is to separate two earnings streams:

1. Durable/recurring — Data Vantage (recurring data/access) + the structurally growing SPX/VIX/0DTE franchise. This deserves a premium multiple (high-20s to ~30×) given the moat, ~66% adjusted operating margins, and secular growth.
2. Cyclical/volume-sensitive — multi-listed options, cash equities, FX, and the volatility-spike portion of index volumes. This deserves a market-to-below-market multiple (mid-teens) given commoditization and cyclicality.

The blended ~24× trailing / ~20–22× forward multiple implies the market is capitalizing a large fraction of 2025’s elevated volumes as durable. If 2025 was a volatility peak, forward earnings will disappoint the trajectory embedded in that multiple. A reverse-DCF sanity check: to justify ~24× on TTM-adjusted EPS, Cboe needs sustained high-single-digit EPS growth from here — achievable if 0DTE/index volumes hold through a normal-vol regime and Data Vantage compounds, but vulnerable to (a) vol mean-reversion and (b) the 2032 license cliff increasingly weighing on the terminal multiple.

10.4 Scenarios (illustrative, financials only — not a target)

• Bull: secular 0DTE/retail adoption persists through a normal-vol environment; Data Vantage compounds high-single-digits; realignment lifts margins toward ~70%; SPX/VIX pricing power holds; net revenue grows mid-to-high single digits organically with margin expansion. In this path ~20–22× forward proves cheap and the multiple re-rates toward CME/NDAQ.
• Base: volumes normalize off the 2025 peak; EPS growth decelerates to mid-single digits; the multiple holds in the low-20s; total return ≈ earnings growth + ~1% dividend.
• Bear: volatility mean-reverts to a sustained low-vol regime; VIX and 0DTE volumes fall; multi-listed/cash-equities share keeps bleeding with fee compression; the 2032 license cliff weighs on the terminal multiple. Earnings stagnate or decline and the multiple de-rates toward ICE’s ~16× forward.

Verdict — the price embeds optimism about the permanence of peak-cycle volumes. It is defensible if 0DTE is structural and the license renews on reasonable terms; it is exposed if either assumption breaks. The most important swing variables are, in order: (1) durability of 0DTE/index volumes through a normal-vol environment; (2) the S&P license renewal; (3) Data Vantage’s organic growth/margin trajectory.

11. Variant Perception

Consensus belief. Cboe is a high-quality, wide-moat, low-beta “compounder with a hedge-like quality” — the SPX/VIX franchise benefits when volatility rises (e.g., if the AI trade unwinds), Data Vantage provides recurring ballast, margins and returns are elite, and the new CEO is sharpening focus. The Street is broadly constructive and the stock trades at a premium to ICE and roughly in line with CME/NDAQ.

Strongest bull case. The proprietary franchise is a regulated monopoly that cannot be competed away on-exchange; 0DTE/retail/international are durable secular growth vectors aligned with the moat; recurring data revenue is rising toward and above ~30% of net revenue, de-risking cyclicality; the realignment lifts margins; and the company is a structurally short-volatility-of-volatility long — it makes more money precisely when markets are scary. At ~20–22× forward, below its own history, that’s a reasonable price for a franchise of this quality.

Strongest bear case. Earnings are at a cyclical and structural high simultaneously; FY2025–Q1’26 records rode a volatility peak that will mean-revert; ~74% of revenue is volume-driven; the commodity tier is bleeding share into a supply boom; and the entire crown jewel is a finite license (2032/2033) on someone else’s index, with undisclosed renewal economics and a counterparty that has its own ambitions. Strip out one-time investment gains and clearing-flow cash distortions and the “record” cash generation looks more pedestrian. A normal-vol year plus any whiff of license risk de-rates the stock toward the mid-teens.

The 3–5 assumptions that matter most:

1. 0DTE/index-options volumes are structurally durable, not a volatility-regime artifact. (Bull’s load-bearing assumption.)
2. The S&P DJI license renews past 2032 on economically reasonable terms. (The terminal-value question.)
3. Data Vantage keeps compounding and the recurring mix keeps rising.
4. Multi-listed/cash-equities erosion stays contained to a small profit pool.
5. Management stays disciplined on capital allocation (no ErisX repeat).

What would falsify each side. Bear falsified: two-plus quarters of sub-16 VIX with SPX/0DTE ADV holding (proves structural durability), plus an early license renewal on disclosed reasonable terms. Bull falsified: a sustained low-vol stretch in which index volumes roll over with the VIX, and/or any 8-K or S&P Global commentary signaling license renegotiation on worse terms or internalization of index derivatives.

12. Fact vs. Interpretation

13. Open Questions

1. S&P DJI license economics and renewal. The per-contract royalty rate and any renewal terms past 2032/2033 are not public. This is the single largest unquantifiable in the thesis. Watch: any 8-K referencing the license; S&P Global’s index-derivatives commentary.
2. 0DTE durability through a low-vol regime. Is 0DTE a structural behavioral shift or a volatility-regime artifact? No full low-vol cycle has yet tested it.
3. Normalized (mid-cycle) earnings. What is EPS at a normalized VIX (~16–18) with 0DTE growth plateauing? A volatility-normalized model is the key analytical next step; if normalized EPS is within ~10% of FY2025, the cyclical-premium concern fades; >20% downside makes ~24× hard to defend.
4. Recurring-mix trajectory. Does Data Vantage + access/capacity push the non-transaction share above ~30%, structurally de-risking cyclicality?
5. Realignment execution. Do the $100–120M cost savings and TMX divestiture actually land, and do the new bets (prediction markets, tokenization, crypto) stay modest rather than becoming the next ErisX?
6. Capital-return signal. At what price do buybacks resume? Resumption is a management valuation tell.

14. What Must Be True

Bull case — for the current price (or higher) to be justified:

• 0DTE/index-options volumes prove structurally durable, holding (or growing) through a normal-volatility environment.
• Data Vantage compounds high-single-digits and the recurring mix rises, lifting the blended multiple’s defensibility.
• The S&P license renews past 2032 on reasonable terms, removing the terminal-value overhang.
• Margins expand toward ~70% on the realignment, and management avoids non-core M&A.
• Falsification test: a sustained sub-16 VIX stretch in which SPX/0DTE ADV rolls over with the VIX — i.e., the volumes were cyclical, not structural — would break the bull case. So would any license-renegotiation signal.

Bear case — for the stock to de-rate materially:

• Volatility mean-reverts to a low-vol regime; VIX and 0DTE volumes fall; index-driven revenue contracts.
• Multi-listed/cash-equities share keeps bleeding with fee compression, and the commodity tier becomes a visible drag.
• The 2032 license cliff begins to weigh on the terminal multiple as it approaches without a disclosed renewal.
• Falsification test: two-plus quarters of sub-16 VIX with SPX/0DTE ADV holding flat-to-up, plus an early, disclosed license renewal on reasonable terms, would refute the bear thesis and validate the structural-growth narrative.

The two cases hinge on the same two variables — 0DTE durability and the license — pointed in opposite directions. That symmetry is why this is a genuinely two-sided, evidence-driven debate rather than a one-way call.

APPENDIX A — Diligence Questionnaire

Labels: Fact / Interpretation / Assumption where material.

General

What thoughtful questions have other investors asked about this company? The 2025–26 earnings-call Q&A clustered on a consistent set: (1) 0DTE sustainability and cannibalization — whether single-name 0DTE options would cannibalize the SPX franchise (management argues additive, not cannibalistic: SPX is cash-settled/European-style with smoother macro moves, single names are physically settled/American-style with fatter tails); (2) Data Vantage growth durability — why guidance stays “mid-to-high single-digit” when recent growth ran higher (management: full-year framing; 45% of new data sales international in Q1’26 vs 35% a year earlier); (3) prediction markets / event contracts strategy and regulatory path; (4) the buyback pause amid record cash; (5) the realignment — workforce cut, divestitures, savings. The real debate is narrower: how cyclical are the record volumes, and how to think about the 2032 S&P license cliff.

Cyclicality & Earnings Nature

Are earnings at a cyclical high or low? At/near a cyclical AND structural high. FY2025 net revenue +17% and Q1’26 +29% rode an unusually volatile tape (VIX closed 52.33 on April 8, 2025; 27.8 in November 2025). Nine of the ten highest SPX volume days on record occurred in Q4’25–Q1’26. Management’s mid-single-digit 2026 organic guide concedes 2025’s pace is not the run-rate.

Driven by the external environment or internal actions? Roughly two-thirds external (volume/volatility), one-third internal (pricing/mix, new products, Data Vantage, cost control). Cboe has real internal levers but cannot manufacture volatility.

How stable are revenues? ~74% transaction/volume-based (cyclical); ~26% recurring (Data Vantage market data + access/capacity), a rising floor.

Outlook for products/services? SPX/VIX/0DTE remains the growth engine but is maturing (0DTE already ~59% of SPX). Data Vantage guided durable mid-to-high single-digit. International is the fastest-growing slice. New optionality (prediction markets, crypto, tokenization) is early-stage with modest 2026 revenue assumptions.

How big will this market be? Large and growing — US listed-options volume hit successive records (2025 ~15.2B contracts, +26%); the index-options and market-data/connectivity TAM is expanding.

Business Quality & Competitive Moat

Is the industry getting more or less competitive? More in multi-listed options and cash equities (~18 US options exchanges → ~20 in 2026; rebate/fee compression). Not at all in Cboe’s proprietary single-listed SPX/VIX products (no on-exchange competitor).

How profitable is the business (ROIC, ROE)? Among the highest in finance: FY2025 GAAP operating margin 60.4% (adjusted ~66%), ROE ~23%, very high return on tangible capital. Peak-cycle returns overstate the mid-cycle level.

How profitable is the industry — competitors, barriers? Operator-level barriers are high (SEC/CFTC registration, OCC common clearing, liquidity network effects, exclusive index licenses). Multi-listed products have ~zero switching cost (fungible via OCC), so that tier is a low-barrier, rebate-competed commodity.

Can the business be easily understood? Moderately complex but understandable.

Can it be undermined by foreign low-cost labor? Largely irrelevant — a technology/licensing/network business (1,661 employees at YE25).

Do brands matter? Enormously — “VIX / the fear gauge” and “SPX” are franchise brands and effectively un-substitutable.

Nature of competition? Product exclusivity in proprietary index products; price/liquidity/technology in multi-listed and equities.

Customers’ switching costs? High for proprietary single-listed products; low for multi-listed options (fungible, OCC-cleared).

Financial Condition & Balance Sheet

Assets not fully recognized on the balance sheet? Substantial — the SPX/VIX franchise value, the S&P DJI license, the VIX brand/methodology, and internally developed technology are largely not capitalized.

Off-balance-sheet liabilities? Operating leases (~$167.7M YE25); purchase obligations ~$1,118.1M (S&P royalty minimums + data/telecom); the S&P DJI royalty; clearing-related contingencies and the Cboe Clear default-guarantee backstop; corporate guarantees; litigation.

How conservative is the accounting? Reasonable. FY2025 GAAP EPS $10.42 vs adjusted $10.67 — a modest gap, driven mainly by acquired-intangible amortization (~$70M) and impairments (~$46.7M), offset by ~$96.8M one-time investment gains. Goodwill $3,150.5M, intangibles net $1,297.2M at YE25.

How CapEx-hungry? Very low — capex ~3% of net revenue ($73–83M guided 2026).

Capital Allocation & Management

How much FCF, and how is it used? Strong, high-conversion. Normalized FCF ~$1.1B (reported FY25 OCF $1,752.6M was inflated ~$528.5M by clearing flows; core OCF ~$1.2B). Uses: organic investment, a ~15-year-growing dividend ($2.88 annualized, ~26% payout), opportunistic buybacks, bolt-on M&A; net leverage ~0.8–0.9× (net cash).

Significant acquisitions recently? Pivoting away from acquisition — recent activity is divestiture (Cboe Canada + Australia to TMX for ~US$300M; wind-downs of Japan, CEDX, listings). The defining prior acquisition was the value-destroying ErisX/Cboe Digital ($460.9M impairment 2022).

Buying back shares? Opportunistically and lumpily — FY25 $65.3M (all early-year), zero in Q4’25 at highs, $45.1M Q1’26; $569.4M authorization remaining at 3/31/26. The pause is a constructive price-discipline signal.

Issuing large amounts of new shares to insiders? No — SBC just $50.4M (~2.1% of net revenue); diluted share count fell ~2% (FY21 107.3M → FY25 105.1M).

Compensation policy of directors/management? CEO Donohue realized 2025 total $18.3M (inflated by a one-time $6.0M sign-on grant); ongoing structure base $1.30M, 150%-of-salary target bonus, 50/50 RSU/PSU LTI (PSU = relative-TSR + EPS). Strong governance (6× ownership guideline, anti-hedging/pledging, clawbacks).

Motivations of management? Equity-heavy pay aligns with shareholders, but personal ownership is thin (all insiders <1%; CEO 2,604 shares).

Valuation & Market Data

ADR / MLP / K-1 issuer? No — standard US C-corporation common stock.

Dividend policy? $0.72/quarter ($2.88 annualized); raised ~14% in August 2025; ~15 consecutive annual increases; payout ~26%; yield ~1.0%.

How profitable? ~60% GAAP operating margin, ~45% net margin (on net revenue), ROE ~23%.

Is net income diverging from cash from operations? Quarter-to-quarter, yes — Cboe Clear margin/clearing-fund movements and Section 31 timing distort OCF. Over a full year, earnings are cash-backed and high-quality.

Risks & Downside

What would cause the stock to decline? Volatility mean-reversion; loss/repricing of the S&P license (2032/33); multi-listed share loss/fee compression; adverse regulation; multiple de-rating.

Risk of a catastrophic loss? Tail risks: a major technology/clearing outage, a clearing-member default exhausting the Cboe Clear backstop, major litigation, or loss of the S&P DJI license (the single largest concentrated risk).

Chance of a total loss? Very low — strong balance sheet, net cash, low leverage, recurring data base.

Recent News & Events

Has the business environment changed recently? Yes — an elevated-volatility regime (2025) layered on structural 0DTE/retail/international adoption produced record results; the question is how much reverts.

Significant acquisitions? None recently; the move is divestiture (TMX) and wind-downs.

Change in accounting policies? Data & Access Solutions rebranded Data Vantage; Digital folded into Futures (Q1’25). No material accounting-policy change otherwise.

Recent changes — new markets, facilities, management? New CEO Craig Donohue (May 7, 2025) succeeding Fred Tomczyk; COO Isaacson retired March 2026; October 2025 strategic realignment (~20% workforce cut, $100–120M targeted savings); new products (DJX dailies, Magnificent 10, Bitcoin/Ether futures, prediction-market Mini-SPX planned Q2’26, SEC-approved extended/24×5 hours).

APPENDIX B — Source Appendix

Primary sources before secondary; recent before stale.

Primary — SEC filings (SEC EDGAR, CIK 0001374310)

Primary — operating data (company-reported)

• Cboe monthly volume & RPC reports / “State of the Options Industry”: SPX (~970.6M) and VIX (~215.6M) FY2025 contract totals; 0DTE share (~59% of SPX); industry 2025 totals (~15.2B contracts, +26%; record single-day volumes).

Secondary — industry, competitor, regulatory (public)

• MIAX 2025 disclosures — record ~18.2% options share Q4’25 (+14.5% YoY).
• MEMX disclosures — ~4% options share; SEC approval (Oct 2025) of a second options exchange (MX2), Q2’26 launch.
• SEC rulemaking record — Rules 610/612 tick-size/access-fee reform (adopted Sept 2024; D.C. Circuit upheld Oct 2025; compliance ~Nov 2025); withdrawal of proposed Order Competition Rule & Reg Best Execution (June 2025).
• TMX Group / Cboe announcement — sale of Cboe Canada + Cboe Australia for ~US$300M (agreed April 22, 2026).
• CBOE Volatility Index (VIX) levels — April 8, 2025 close 52.33; November 2025 ~27.8.
• Public market data (price, market cap, multiples, peer comps for ICE, CME, NDAQ) as of June 5, 2026.

This article is an independent analysis and general information only — it is not investment advice. The body (Sections 1–15) takes no position and sets no price target; the opening “Author’s Take” is the author’s own opinion. Figures are as of the dates shown; market data as of June 5, 2026 unless noted.